|
Live online
Classroom
|
2025 |
2026 |
| Sep |
Oct |
Nov |
Dec |
Jan |
Mar |
Mar |
Apr |
May |
Jun |
Jul |
Aug |
| A Practical Approach to Developing the CMC Package for Veterinary Pharmaceutical Products |
Regulatory Affairs |
|
|
4 |
|
|
|
|
|
7 |
|
|
|
| A Practical Approach to Veterinary Vaccine Development and Registration in the EU |
Regulatory Affairs |
|
|
6-7 |
|
|
10-11 |
10-11 |
|
|
|
|
|
| A Practical Guide to Producing and Maintaining the PSMF |
Vigilance |
|
3 |
|
|
|
|
|
|
|
|
|
|
| A Practical Guide to Writing Risk Management Plans (RMPs) |
Vigilance |
|
|
12 |
|
|
20 |
20 |
|
|
|
|
|
| A Practical Introduction to Good Clinical Practice (GCP) |
GxP |
|
|
|
|
|
|
|
15 |
|
|
|
|
| A Regulatory Update on the Medical Device and In-Vitro Diagnostic Regulations in the EU and UK |
Regulatory Affairs |
|
21 |
|
|
|
|
|
29 |
|
|
|
|
| AI & ML in Clinical Trials: Fundamentals, Applications, and Regulatory Aspects |
Artificial Intelligence (AI) in Life Sciences |
|
|
6 |
|
|
|
|
|
6 |
|
|
|
| AI in Pharmacovigilance |
Artificial Intelligence (AI) in Life Sciences |
|
|
19 |
|
|
|
|
|
|
|
|
|
| Achieving Publication Success in Scientific Journals |
Medical Writing |
|
|
3 |
|
|
2 |
2 |
|
|
|
|
|
| Additional Risk Minimization Measures (aRMMs) and Their Effectiveness |
Vigilance |
|
|
|
3 |
|
|
|
|
|
|
|
|
| Advanced Pharmacovigilance: From Performing Successful Due Diligence to Benefit-Risk Assessments – What to Consider |
Vigilance |
|
9-10 |
|
|
|
23-25 |
23-25 |
|
|
|
|
|
| Advanced Reinsurance Contracts and Disputes Masterclass |
Contract Wordings |
|
1 |
|
|
|
|
|
|
6 |
|
|
|
| Advanced Understanding and Drafting Oil and Gas Industry Contracts |
Commercial Contracts |
|
|
17 |
|
|
|
|
|
8 |
|
|
|
| Advanced Veterinary Pharmacovigilance |
Vigilance |
|
15-16 |
|
|
|
|
|
|
21-22 |
|
|
|
| An Essential Overview of Medical Information |
Regulatory Affairs |
|
|
|
4 |
|
|
|
|
|
22 |
|
|
| An Essential Overview of the Pharmaceutical and Biotech Industries |
Regulatory Affairs |
|
|
|
|
|
12 |
12 |
|
|
|
|
|
| An Introduction to Ethylene Oxide (EO) Sterilization for Medical Devices |
GxP |
|
|
10 |
|
|
|
|
|
14 |
|
|
|
| An Introduction to Human Factors for Pharmaceutical and Medical Device Professionals |
Regulatory Affairs |
|
|
20 |
|
|
|
|
|
8 |
|
|
|
| An Introduction to ISO 11607 - Packaging for Terminally Sterilized Medical Devices |
GxP |
|
|
17 |
|
|
|
|
|
|
|
|
|
| An Introduction to ISO 13485: 2016 - Quality Management System (QMS) for Medical Devices |
GxP |
|
|
19 |
|
|
|
|
|
21 |
|
|
|
| An Introduction to Signal Detection |
Vigilance |
|
15 |
|
|
|
|
|
16 |
|
|
|
|
| An Introduction to Technology Transfer for Solid Dosage Forms |
GxP |
|
|
14 |
|
|
6 |
6 |
|
|
|
|
|
| An Introduction to the Design and Development of Medical Devices |
Medical Technology |
|
|
|
10-11 |
|
|
|
|
|
29-30 |
|
|
| An Introduction to the Medical Device Regulation |
Regulatory Affairs |
|
|
3-5 |
|
|
|
|
|
|
|
|
|
| An Overview of Ethical Standards in Clinical Research Publication |
GxP |
|
|
|
|
|
|
|
|
13 |
|
|
|
| An introduction to Risk Management ISO 14971:2019 |
Regulatory Affairs |
|
|
11 |
|
|
|
|
27 |
|
|
|
|
| Animal Feed and Feed Additive Registration in China and Thailand |
Regulatory Affairs |
|
23 |
|
|
|
|
|
16 |
|
|
|
|
| Antimicrobial Resistance (AMR) and 'One Health': Current Challenges, Regulatory Frontiers and Future Solutions |
Regulatory Affairs |
|
|
|
10 |
|
|
|
|
|
10 |
|
|
| Balancing Costs and Compliance: The Financial Side of GMP |
GxP |
|
|
|
|
|
|
|
|
|
|
|
|
| Best Practice for Writing Effective SOPs |
Regulatory Affairs |
|
|
|
4 |
|
26 |
26 |
|
|
|
14 |
|
| Best Practices for Supplier Qualification in Life Science |
GxP |
|
|
13-14 |
|
|
|
|
|
6-7 |
|
|
|
| Biological Evaluation of Medical Devices |
Regulatory Affairs |
|
|
|
|
21-22 |
|
|
|
|
|
13-14 |
|
| Biosimilars |
Biopharma |
30-1 |
|
|
|
|
16-17 |
16-17 |
|
|
|
|
|
| Biotechnology for the Non-Biotechnologist |
Biopharma |
|
|
10-14 |
|
|
|
|
|
|
|
|
|
| Building The Business Case For Pharma 4.0 |
Medical Technology |
|
|
|
|
|
|
|
13 |
|
|
|
|
| CAPA (Corrective and Preventative Action) |
Regulatory Affairs |
|
|
|
5 |
|
|
|
|
|
15 |
|
|
| Chemistry, Manufacture and Control (CMC) - Regulatory Requirements for Biological Drug Products |
GxP |
|
20-21 |
|
|
|
|
|
23-24 |
|
|
|
|
| Classification of Software as a Medical Device (SaMD) and Medical Device Software (MDSW) |
Regulatory Affairs |
|
|
12 |
|
|
|
|
|
|
|
|
|
| Cleaning Validation - Best Practice in Pharmaceuticals |
GxP |
|
|
|
2-3 |
|
|
|
|
|
23-24 |
|
|
| Cleanroom Requirements for Medical Device Manufacturers |
Regulatory Affairs |
|
|
|
|
|
|
|
|
|
|
|
|
| Clinical & Post-Marketing Safety |
Vigilance |
|
|
|
|
|
|
|
|
11-12 |
|
|
|
| Clinical Evaluation of Medical Device Software and Software as a Medical Device |
Clinical Research |
|
|
|
|
|
|
|
28 |
|
|
|
|
| Clinical Evaluation of Medical Devices: The Clinical Evaluation Report |
Clinical Research |
|
|
25-26 |
|
|
|
|
|
|
|
|
|
| Clinical Overview and Clinical Summary: Creating Effective Marketing Authorisation Application |
Regulatory Affairs |
|
|
|
|
|
16-17 |
16-17 |
|
|
|
|
|
| Clinical Quality Management Systems |
Clinical Research |
18-19 |
|
|
|
|
23-24 |
23-24 |
|
|
|
|
|
| Clinical Trial Agreements: Key Legal, Regulatory and IP Considerations for the EU and UK Markets |
Commercial Contracts |
|
|
28 |
|
|
18 |
18 |
|
|
|
2 |
|
| Clinical Trial Monitoring |
Clinical Research |
|
|
|
|
|
|
|
|
|
29-30 |
|
|
| Clinical Trial Regulatory Requirements |
Clinical Research |
|
|
|
|
|
2-3 |
2-3 |
|
|
|
|
|
| Competition Law for the Pharmaceutical Industry |
Commercial Contracts |
|
10 |
|
|
|
|
|
|
|
|
|
|
| Conflict Management for Pharmaceutical Executives |
Conflict Management |
|
|
|
|
26-29 |
|
|
|
|
|
13-16 |
|
| Cosmetovigilance |
Vigilance |
|
13-14 |
|
|
|
|
|
|
|
18-19 |
|
|
| Cyber Security for Medical Devices |
Regulatory Affairs |
|
|
|
|
|
19-20 |
19-20 |
|
|
|
|
|
| Data Innovation for AI-enabled Medical Devices |
Artificial Intelligence (AI) in Life Sciences |
|
|
12 |
|
|
|
|
|
|
|
|
|
| Data Integrity Auditor Masterclass |
GxP |
|
15-16 |
|
|
|
|
|
22-23 |
|
|
|
|
| Data Integrity and Document Management |
GxP |
|
|
|
11 |
|
|
|
|
|
22 |
|
|
| Dealing With Scientific Journal Reviewers: From Comments to Resubmission |
Medical Writing |
|
|
24 |
|
|
|
|
|
|
15 |
|
|
| Demystifying European Post-Marketing Pharmacovigilance |
Vigilance |
|
|
3-7 |
|
|
|
|
|
|
|
|
|
| Developing and Managing Software as a Medical Device (SaMD) and Medical Device Software (MDSW) |
Regulatory Affairs |
|
|
13 |
|
|
|
|
|
|
|
|
|
| Development of Combination Products: Critical Interactions |
GxP |
|
|
|
|
|
|
|
|
|
|
|
|
| Digital CMC |
Medical Technology |
|
|
|
|
|
|
|
|
6 |
|
|
|
| Digital CMC: The Key To Realising Pharma 4.0 |
GxP |
|
|
|
1 |
|
|
|
|
|
23 |
|
|
| Digital Technology Transfers |
Medical Technology |
|
|
|
|
|
4 |
4 |
|
|
|
|
|
| Digital Technology and Personalisation in Patient Support Programmes |
Clinical Research |
|
|
5 |
|
|
|
|
|
6 |
|
|
|
| Drafting Commercial Contracts for the Pharmaceutical Industry |
Commercial Contracts |
|
|
12-13 |
|
|
|
|
|
20-21 |
|
|
|
| Drafting Renewable Energy Contracts: Clearer Terms, Stronger Projects and Better Outcomes |
Energy |
|
|
|
|
|
|
|
|
|
|
|
|
| EU Pharmaceutical Regulations and Strategy |
Regulatory Affairs |
|
|
|
|
|
2-3 |
2-3 |
|
|
|
|
|
| EU Proposed Pharmaceutical Legislation Changes |
Regulatory Affairs |
|
|
|
|
19 |
|
|
|
|
|
1 |
|
| Effective Change Management in Pharma |
GxP |
|
10 |
|
|
|
|
|
17 |
|
|
|
|
| Effective Communication & Negotiation in Technology Transfers |
GxP |
|
|
3 |
|
|
|
|
|
18 |
|
|
|
| Effective Deviation Management Systems in Pharma |
GxP |
|
|
|
|
|
20 |
20 |
|
|
|
|
|
| Effective Regulatory Compliance for Storage and Distribution in Pharma Supply Chains |
GxP |
|
|
21 |
|
|
|
|
|
15 |
|
|
|
| Effective Technical Writing & Editing |
Medical Writing |
30 |
|
|
|
|
|
|
|
15 |
|
|
|
| Effective Technology Transfer |
GxP |
|
6-7 |
|
|
|
|
|
|
|
|
|
|
| Ensuring Clinical Research Quality & Patient Safety |
GxP |
|
|
|
|
|
|
|
|
|
|
|
|
| Essential Documentation Skills for Clinical Research Compliance |
GxP |
|
|
|
|
|
9 |
9 |
|
|
|
|
|
| FDA Approval Process for Medical Devices |
Regulatory Affairs |
|
|
|
2-3 |
|
|
|
|
|
30-1 |
|
|
| GCP and Clinical Research Update - Hot Inspection Topics |
Clinical Research |
|
|
21 |
|
|
|
|
|
19 |
|
|
|
| GMP Principles in Vaccine Manufacturing |
GxP |
|
|
|
10-11 |
|
|
|
|
|
16-17 |
|
|
| Global Market Access for Medical Device Software |
Regulatory Affairs |
|
|
|
1-2 |
|
|
|
|
|
8-9 |
|
|
| Golden Rules of Being a Successful GMP Auditor |
GxP |
|
|
|
|
|
|
|
|
|
|
|
|
| Good Distribution Practices of Pharmaceuticals and APIs |
GxP |
|
|
17-18 |
|
|
|
|
|
14-15 |
|
|
|
| Good Writing Practice for Clinical Research: Ethics, Standards & Compliance |
GxP |
|
|
|
|
|
|
|
20 |
|
|
|
|
| How to Audit Pharmaceutical Suppliers (Material and Service) |
GxP |
|
|
|
|
|
|
|
|
|
|
|
|
| How to Deal with Difficult Situations in GMP Audits |
GxP |
|
|
6 |
|
|
5 |
5 |
|
|
|
|
|
| How to Interview During GMP Audits |
GxP |
|
|
10 |
|
|
12 |
12 |
|
|
|
|
|
| How to Manage Internal GMP Audits |
GxP |
|
20-21 |
|
|
|
|
|
|
|
|
|
|
| How to Pass International Health Authority Inspections |
GxP |
|
|
|
|
|
|
|
16-17 |
|
|
|
|
| How to Perform Bullet-Proof Good Distribution Practices (GDP) and Good Storage Practices (GSP) Audits |
GxP |
|
|
|
3-4 |
|
|
|
|
|
18-19 |
|
|
| Human Factors and Usability Engineering in the Development of Drug Delivery Products |
Regulatory Affairs |
|
|
|
|
|
|
|
|
|
|
|
|
| Interpersonal Project Management Skills for the Life Sciences Industries |
Project Management |
|
|
|
|
22-23 |
|
|
|
|
|
16-17 |
|
| Introduction to Veterinary Pharmacovigilance |
Vigilance |
|
|
5-6 |
|
|
9-10 |
9-10 |
|
|
|
|
|
| Introduction to the In-Vitro Diagnostic Regulation (IVDR) |
Regulatory Affairs |
|
|
|
|
|
|
|
16-17 |
|
|
|
|
| Key Current Issues and Best Practice for Managing Reinsurance Claims |
Claims |
|
|
|
|
|
|
|
30 |
|
|
|
|
| Literature Searching in Drug Safety |
Vigilance |
|
|
|
|
|
|
|
|
19-20 |
|
|
|
| MBA Strategic Thinking for Pharma and Biopharma Professionals |
Leadership & Strategy |
|
2-3 |
|
|
|
|
|
|
|
|
|
|
| Managing Human Error: A Strategic Approach for Pharmaceutical Managers |
Health & Safety |
|
|
|
|
28 |
|
|
|
|
|
1 |
|
| Managing Service Providers including CRO and CMOs oversight to comply with ICH GCP R3 |
Clinical Research |
|
16-17 |
|
|
|
|
|
13-14 |
|
|
|
|
| Market Authorisation of Software as a Medical Device (SaMD) and Medical Device Software (MDSW) |
Regulatory Affairs |
|
|
10-11 |
|
|
|
|
|
|
|
|
|
| Masterclass: Market Authorisation of AI-enabled Medical Devices |
Artificial Intelligence (AI) in Life Sciences |
|
|
18-19 |
|
|
|
|
|
|
29-30 |
|
|
| Mastering CTD Submissions in the MENA Region |
Regulatory Affairs |
|
|
28 |
|
|
|
|
|
19 |
|
|
|
| Mastering Ethical and Effective Scientific Publishing: Applying Good Publication Practice (GPP) |
Medical Writing |
|
|
|
|
20 |
|
|
|
|
|
8 |
|
| Mastering Grant Writing: Essential Skills for Crafting Winning Proposals |
Medical Writing |
|
9-10 |
|
|
|
|
|
|
|
22-23 |
|
|
| Medical Device Regulation in the Eurasian Union, Russia and the CIS |
Regulatory Affairs |
|
|
|
9-10 |
|
|
|
|
|
30-1 |
|
|
| Medical Device Regulations in Asia-Pacific Markets |
Regulatory Affairs |
|
|
3-4 |
|
|
3-4 |
3-4 |
|
|
|
|
|
| Medical Device Regulations in the Middle East and North Africa |
Regulatory Affairs |
|
|
19-20 |
|
|
|
|
|
18-19 |
|
|
|
| Medical Device Single Audit Programme (MDSAP) |
GxP |
|
|
26-27 |
|
|
|
|
|
|
25-26 |
|
|
| Medical Device Studies: Clinical Evidence |
Clinical Research |
|
15-16 |
|
|
|
|
|
|
|
|
|
|
| Medical Editing for Peer-Reviewed Journals |
Medical Writing |
|
|
|
|
|
|
|
|
8 |
|
|
|
| Medical Writing Excellence: Crafting Compelling Scientific Documents |
Medical Writing |
|
|
|
|
|
|
|
|
|
|
|
|
| Medical Writing for Consumers |
Medical Writing |
|
|
|
|
|
|
|
21 |
|
|
|
|
| Medical Writing for Medical Devices |
Medical Writing |
|
|
20-21 |
|
|
|
|
|
|
25-26 |
|
|
| Medical Writing with AI |
Artificial Intelligence (AI) in Life Sciences |
|
15 |
|
|
|
|
|
|
|
18 |
|
|
| Metered Dose Inhaler (MDI) Technology |
Medical Technology |
|
|
|
|
|
|
|
27-28 |
|
|
|
|
| Metrics and Earned Value in Clinical Research Projects |
Clinical Research |
|
|
24 |
|
|
|
|
|
6 |
|
|
|
| Microbiomics in Clinical Trials |
Clinical Research |
|
|
|
|
|
|
|
|
|
|
|
|
| Modern Agile Leadership for Pharma and Biopharma Professionals: Adapting to a Changing Workplace |
Leadership & Strategy |
|
|
17-18 |
|
|
|
|
|
11-12 |
|
|
|
| Molecular Biology for the Non-Molecular Biologist |
Biopharma |
|
|
|
|
|
|
|
20-21 |
|
|
|
|
| Navigating EU and FDA Regulations for Drug/Device and Device/Drug Combination Products |
Regulatory Affairs |
|
|
|
|
|
2-3 |
2-3 |
|
|
|
|
|
| Navigating ICH GCP E6 (R3): What You Need to Know |
Clinical Research |
|
|
|
|
29 |
|
|
|
|
|
13 |
|
| Navigating Regulatory Compliance Whilst Developing and Distributing Polymerase Chain Reaction (PCR)-Based IVD Tests |
Regulatory Affairs |
|
|
6 |
|
|
|
|
|
15 |
|
|
|
| New EU GMP Annex 1: Compliant Aseptic Operations |
GxP |
|
|
25-27 |
|
|
|
|
|
19-21 |
|
|
|
| Non-Conformance and Corrective Action for Medical Device Manufacturers |
Regulatory Affairs |
|
|
|
11 |
|
|
|
|
|
19 |
|
|
| Orphan Drug Regulatory Masterclass: EU & US Insights |
Regulatory Affairs |
|
14 |
|
|
|
4 |
4 |
|
|
|
|
|
| Overview of EU and UK Regulatory Affairs |
Regulatory Affairs |
|
|
|
|
|
|
|
|
|
|
|
|
| Pharmaceutical Development of ATMPs |
GxP |
|
13-14 |
|
|
|
18-19 |
18-19 |
|
|
|
|
|
| Pharmaceutical Packaging Essentials: From Regulatory Compliance to Market Success |
GxP |
|
|
|
|
26-28 |
|
|
|
|
|
6-8 |
|
| Pharmaceutical Regulatory Affairs in Africa |
Regulatory Affairs |
|
|
4-5 |
|
|
|
|
|
6-7 |
|
|
|
| Pharmaceutical Regulatory Affairs in Asia |
Regulatory Affairs |
|
8-10 |
|
|
|
|
|
|
|
|
|
|
| Pharmaceutical Regulatory Affairs in China |
Regulatory Affairs |
|
|
26-27 |
|
|
|
|
|
12-13 |
|
|
|
| Pharmaceutical Regulatory Affairs in Russia and the Eurasian Union |
Regulatory Affairs |
|
|
|
|
|
5-6 |
5-6 |
|
|
|
|
|
| Pharmaceutical Regulatory Affairs in the Middle East |
Regulatory Affairs |
|
|
|
|
|
|
|
|
|
|
|
|
| Pharmaceutical Regulatory Affairs in the Middle East and North Africa |
Regulatory Affairs |
|
21-23 |
|
|
|
|
|
|
|
|
|
|
| Pharmacovigilance Aspects of Licensing Agreements |
Vigilance |
|
|
|
1-2 |
|
|
|
|
|
25 |
|
|
| Pharmacovigilance QMS & Inspection Preparation |
Vigilance |
25-26 |
|
|
|
|
|
|
27-28 |
|
|
|
|
| Pharmacovigilance: An Overview of Drug Safety from Safety Collection to Regulatory Inspection |
Vigilance |
|
|
|
|
|
|
|
30 |
|
|
|
|
| Positive Persuading and Influencing Skills for Pharma Professionals |
Management |
|
|
10-13 |
|
|
|
|
|
18-21 |
|
|
|
| Post-Market Surveillance and Vigilance of Software as a Medical Device (SaMD) and Medical Device Software (MDSW) |
Vigilance |
|
|
|
3-4 |
|
|
|
|
|
10-11 |
|
|
| Practical Implementation of GCP in Veterinary Field Studies |
GxP |
|
|
25-26 |
|
|
|
|
|
13-14 |
|
|
|
| Practical Requirements of the Arab Pharmacovigilance Guidelines |
Vigilance |
|
16-17 |
|
|
|
|
|
21-22 |
|
|
|
|
| Pre-Filled Syringes: End-to-End Processing |
Medical Technology |
|
|
5-6 |
|
|
|
|
|
11-12 |
|
|
|
| Process Validation for Medical Devices |
GxP |
|
22-23 |
|
|
|
|
|
|
|
4-5 |
|
|
| Project Management for Pharma Professionals |
Project Management |
|
|
10-11 |
|
|
9-10 |
9-10 |
|
|
|
2-3 |
|
| Protein Engineering for Pharmaceutical Biotechnology |
Biopharma |
|
|
|
|
21-22 |
|
|
|
|
|
7-8 |
|
| Real World Evidence (RWE), Real World Data (RWD) and the Application of Artificial Intelligence (AI) in Pharma |
Artificial Intelligence (AI) in Life Sciences |
|
|
19 |
|
|
|
|
|
|
22 |
|
|
| Registration of Veterinary Pharmaceuticals in China |
Regulatory Affairs |
|
23 |
|
|
|
|
|
16 |
|
|
|
|
| Regulatory Compliance and Safety Standards for Aesthetic Devices |
Regulatory Affairs |
|
|
|
5 |
|
|
|
|
|
12 |
|
|
| Renewable Energy Law and Regulation: Legal foundations for the renewable energy era |
0 |
|
|
|
|
29-30 |
|
|
|
|
|
2-3 |
|
| Root Cause Analysis and Critical Thinking |
Management |
|
|
24 |
|
|
|
|
|
18 |
|
|
|
| Selecting the Best Scientific Journal for Your Research |
Medical Writing |
|
|
10 |
|
|
|
|
13 |
|
|
|
|
| Signal Detection and Regulatory Expectations |
Vigilance |
|
|
18-21 |
|
|
|
|
|
|
|
|
|
| Signal Detection: A Comprehensive Introduction |
Vigilance |
|
|
|
|
28 |
|
|
|
|
|
1 |
|
| Smart Packaging and Electronic Patient Information |
GxP |
|
|
3-4 |
|
|
|
|
|
15 |
|
|
|
| Software Automation in Research and Development (R&D) Clinical Trials |
Clinical Research |
|
|
|
|
|
17 |
17 |
|
|
|
|
|
| Stability Testing of Pharmaceuticals and Biopharmaceuticals |
GxP |
|
|
10-11 |
|
|
|
|
|
20-21 |
|
|
|
| Sterilization of Medical Devices |
GxP |
|
16-17 |
|
|
|
|
|
23-24 |
|
|
|
|
| Successful Cognitive Testing in Clinical Drug Trials: Biomarkers, Test Selection & Integration |
Clinical Research |
|
|
|
|
|
16 |
16 |
|
|
|
|
|
| Successful Medical Writing – from Protocol to CTD |
Medical Writing |
|
|
|
|
|
23-24 |
23-24 |
|
|
|
|
|
| Sustainable Product Design for MedTech Engineers and Developers |
Medical Technology |
|
|
27 |
|
|
|
|
|
7 |
|
|
|
| The 2024 EU AI Act |
Artificial Intelligence (AI) in Life Sciences |
|
|
|
|
|
|
|
|
|
23 |
|
|
| The Animal Health Summer School: Working Through Veterinary Drug Development in the EU and USA |
Regulatory Affairs |
|
|
|
|
|
|
|
|
|
15-18 |
|
|
| The Applications of Nanoparticles in the Pharmaceutical and Biomedical Industries |
Biopharma |
|
|
12-13 |
|
|
11-12 |
11-12 |
|
|
|
|
|
| The Common Technical Document |
GxP |
|
|
24-25 |
|
27-28 |
|
|
14-15 |
|
|
|
|
| The FDA Drug Approval Process |
Regulatory Affairs |
|
7-8 |
|
|
|
|
|
|
|
|
|
|
| The Financial Benefits of Change Management |
GxP |
|
|
|
|
|
|
|
|
13 |
|
|
|
| The Financial Benefits of Pharmaceutical Quality Systems |
GxP |
|
|
|
|
|
|
|
|
|
|
|
|
| The Financial Benefits of Quality Risk Management |
GxP |
|
|
|
|
|
|
|
17 |
|
|
|
|
| The Financial Benefits of Validation Master Plans |
GxP |
|
|
|
|
|
6 |
6 |
|
|
|
|
|
| The Future of Manufacturing: 3D Printing for Medical Devices |
Medical Technology |
|
|
|
10 |
|
|
|
|
|
17 |
|
|
| The Pharma Mini MBA |
Leadership & Strategy |
|
|
5-7 |
|
|
18-20 |
18-20 |
|
|
|
8-10 |
|
| The Regulatory Requirements on Nitrosamines in the Pharmaceutical Industry |
Regulatory Affairs |
|
13-14 |
|
|
|
|
|
20-21 |
|
|
|
|
| The Role of the Person Responsible for Regulatory Compliance (PRRC) Under the MDR and IVDR |
Regulatory Affairs |
22 |
|
|
|
|
4 |
4 |
|
|
|
|
|
| Thinking Outside of the GMP Box |
GxP |
|
|
|
|
|
|
|
|
|
|
|
|
| UK Conformity Assessed (UKCA) Marking for Medical Devices |
Regulatory Affairs |
|
21 |
|
|
|
|
|
15 |
|
|
|
|
| US FDA - Understanding Key Factors When Working with the FDA |
Biopharma |
|
|
26 |
|
|
|
|
|
12 |
|
|
|
| Understanding Active Pharmaceutical Ingredients (APIs) |
GxP |
|
|
19-20 |
|
|
|
|
29-30 |
|
|
|
|
| Understanding Computer System Validation (CSV) |
GxP |
|
|
24-25 |
|
|
|
|
|
|
17-18 |
|
|
| Understanding Scientific Journal Submission and Publication |
Medical Writing |
|
|
17 |
|
|
|
|
|
11 |
|
|
|
| Understanding and Drafting Oil and Gas Industry Contracts |
Commercial Contracts |
|
|
|
|
|
|
|
|
|
|
|
|
| Understanding the Reinsurance Industry |
Contract Wordings |
|
|
12-13 |
|
|
18-19 |
18-19 |
|
|
|
|
|
| Unique Device Identification (UDI) and Labelling for Medical Device Manufacturers |
Regulatory Affairs |
|
|
20 |
|
|
|
|
|
|
8 |
|
|
| Upstream and Downstream Manufacturing in the Biopharmaceutical Industry |
GxP |
|
|
|
5 |
|
|
|
|
|
11 |
|
|
| Utilising Patient Adherence Data and Digital Tools to Improve Patient Outcomes |
Clinical Research |
|
|
|
|
|
|
|
16 |
|
|
|
|
| Variations to Marketing Authorisations |
Regulatory Affairs |
|
15-16 |
|
|
|
|
|
|
|
2-3 |
|
|
| Veterinary Pharmaceutical Submissions in the EU |
Regulatory Affairs |
|
|
25-26 |
|
|
|
|
|
18-19 |
|
|
|
| Working with Emotional Intelligence in the Pharmaceutical and Biopharma Industry |
Leadership & Strategy |
|
20 |
|
|
|
|
|
27 |
|
|
|
|